A Phase 2 interventional study of CJC-1134-PC and Placebo in Type 2 Diabetes Mellitus, sponsored by ConjuChem. Completed at 1 site in Canada. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2017-06-02.
Sponsored by ConjuChem · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 756 studies in Diabetes Mellitus, Type 2 with a site in Canada — 81 open to participants now, 112 under way, 25 of them phase 3. Diabetes Mellitus, Type 2 · Canada.
Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada, this one is the 413th largest by enrollment of the 673 interventional ones that give a count, is one of 46 that started in 2008, is one of 107 in phase 2, and was the 113th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →81 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada are open now. Recruiting first, the newest first:
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18–80
Amgen · Sites in Canada, United States
Ages 18+
May Faraj, PDt, PhD · Sites in Canada
Ages 40–70 · Healthy volunteers
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
Boehringer Ingelheim · Sites in Canada, United States, Australia and 3 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 25 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
756 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 122 · Phase 3 267 · Phase 4 66
First in 1999; this study’s year is marked. 46 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 227 across the 673 interventional studies, 300 across the 82 observational. Of the 594 that completed or were terminated, 272 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
412 of 756 have an industry lead sponsor. The 10 most frequent:
ConjuChem is the lead sponsor of 4 studies on the registry; none are open to participants now.
ConjuChem has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
37 of the studies in Diabetes Mellitus, Type 2 with a site in Canada that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059377Phase 3Ottawa Heart Institute Research CorporationSemaglutide for Smoking Cessation in Patients With Diabetes | 2026-12 |
| NCT05427084Phase 3Ottawa Heart Institute Research CorporationCanagliflozin Targeting Vascular Inflammation | 2026-12 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT05776420Phase 3Unity Health TorontoEffect of a Healthy Food Voucher on Blood Glucose Control in People With Type 2 Diabetes or Prediabetes | 2027-04-01 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
Add all 37 to your calendar (.ics) → With an account.
Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study.
The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients with type 2 diabetes mellitus who are currently on metformin monotherapy.
Major Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
12 weekly doses of 1.5 mg CJC-1134-PC
Drug: CJC-1134-PC
4 weekly doses of 1.5 mg CJC-1134-PC followed by 8 weekly doses of 2.0 mg CJC-1134-PC
Drug: CJC-1134-PC
12 weekly doses of placebo
Drug: Placebo
1.5 or 2.0 mg CJC-1134-PC
Placebo
Reduction of HbA1c From Baseline
Change from Baseline
Time frame: Screening and Day 85
Reduction in FPG From Baseline
Change from Baseline
Time frame: Screening and Day 85
Reduction in Fasting Body Weight From Baseline
Change from Baseline
Time frame: Screening and Day 85
| Milestone | 1.5 mg CJC-1134-PC | 1.5 or 2.0 mg CJC-1134-PC | Placebo |
|---|---|---|---|
| Started | 50 | 52 | 58 |
| Completed | 43 | 37 | 46 |
| Not completed | 7 | 15 | 12 |
Change from Baseline
| Percent (%) | 1.5 mg CJC-1134-PC | 1.5 or 2.0 mg CJC-1134-PC | Placebo |
|---|---|---|---|
| Reduction of HbA1c From Baseline | -0.85 ± 0.883 | -0.80 ± 0.827 | -0.46 ± 0.744 |
Change from Baseline
| mg/dL | 1.5 mg CJC-1134-PC | 1.5 or 2.0 mg CJC-1134-PC | Placebo |
|---|---|---|---|
| Reduction in FPG From Baseline | -13.48 ± 34.579 | -18.76 ± 36.736 | -10.06 ± 34.137 |
Change from Baseline
| kg | 1.5 mg CJC-1134-PC | 1.5 or 2.0 mg CJC-1134-PC | Placebo |
|---|---|---|---|
| Reduction in Fasting Body Weight From Baseline | -1.98 ± 2.438 | -1.25 ± 2.106 | -1.58 ± 2.374 |
Collected over 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.5 mg CJC-1134-PC | 0/49 (0%) | 0/49 (0%) | 36/49 (73.5%) |
| 1.5 or 2.0 mg CJC-1134-PC | 0/49 (0%) | 0/49 (0%) | 30/49 (61.2%) |
| Placebo | 0/57 (0%) | 0/57 (0%) | 34/57 (59.6%) |
| Event | 1.5 mg CJC-1134-PC | 1.5 or 2.0 mg CJC-1134-PC | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 11/49 | 15/49 | 9/57 |
| HeadacheNervous system disorders | 5/49 | 2/49 | 9/57 |
| DiarrheaGastrointestinal disorders | 6/49 | 6/49 | 3/57 |
| VomitingGastrointestinal disorders | 6/49 | 2/49 | 2/57 |
| DizzinessNervous system disorders | 2/49 | 2/49 | 4/57 |
| Urinary tract infectionInfections and infestations | 3/49 | 1/49 | 2/57 |
| AnorexiaMetabolism and nutrition disorders | 2/49 | 3/49 | 0/57 |
| Back painMusculoskeletal and connective tissue disorders | 0/49 | 3/49 | 1/57 |
| Injection site bruisingGeneral disorders | 0/49 | 0/49 | 3/57 |
| NasopharyngitisInfections and infestations | 2/49 | 2/49 | 3/57 |
Safety Population
| Age, Continuous(years) | 1.5 mg CJC-1134-PC | 1.5 or 2.0 mg CJC-1134-PC | Placebo | Total |
|---|---|---|---|---|
| Mean | 55.2 ± 10.46 | 55.1 ± 12.24 | 57.2 ± 13.05 | 55.9 ± 11.99 |
| Sex: Female, Male(Participants) | 1.5 mg CJC-1134-PC | 1.5 or 2.0 mg CJC-1134-PC | Placebo | Total |
|---|---|---|---|---|
| Female | 21 | 28 | 30 | 79 |
| Male | 28 | 21 | 27 | 76 |
| Ethnicity (NIH/OMB)(Participants) | 1.5 mg CJC-1134-PC | 1.5 or 2.0 mg CJC-1134-PC | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 8 | 5 | 17 |
| Not Hispanic or Latino | 45 | 41 | 52 | 138 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 1.5 mg CJC-1134-PC | 1.5 or 2.0 mg CJC-1134-PC | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 2 |
| Asian | 4 | 5 | 9 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 9 | 7 | 25 |
| White | 34 | 33 | 36 | 103 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 4 | 7 |
The record gives a start of Feb 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 8 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albenatide
ConjuChem